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Abstract: Although the introduction of antiretroviral therapy has reduced the prevalence of
severe forms of neurocognitive disorders, human immunodeficiency virus (HIV)-1-associated
neurocognitive disorders were observed in 50% of HIV-infected patients globally. The blood–
brain barrier is known to be impermeable to most of antiretroviral drugs. Successful delivery
of antiretroviral drugs into the brain may induce an inflammatory response, which may further
induce neurotoxicity. Therefore, alternate options to antiretroviral drugs for decreasing the HIV
infection and neurotoxicity may help in reducing neurocognitive impairments observed in HIVinfected patients. In this study, we explored the role of magnetic nanoparticle (MNP)-bound tissue
inhibitor of metalloproteinase-1 (TIMP1) protein in reducing HIV infection levels, oxidative
stress, and recovering spine density in HIV-infected SK-N-MC neuroblastoma cells. We did not
observe any neuronal cytotoxicity with either the free TIMP1 or MNP-bound TIMP1 used in our
study. We observed significantly reduced HIV infection in both solution phase and in MNP-bound
TIMP1-exposed neuronal cells. Furthermore, we also observed significantly reduced reactive
oxygen species production in both the test groups compared to the neuronal cells infected with
HIV alone. To observe the effect of both soluble-phase TIMP1 and MNP-bound TIMP1 on spine
density in HIV-infected neuronal cells, confocal microscopy was used. We observed significant
recovery of spine density in both the test groups when compared to the cells infected with HIV
alone, indicting the neuroprotective effect of TIMP1. Therefore, our results suggest that the
MNP-bound TIMP1 delivery method across the blood–brain barrier can be used for reducing
HIV infectivity in brain tissue and neuronal toxicity in HIV-infected patients.
Keywords: HIV, neurocognitive disorders, TIMP1, magnetic nanoparticles, blood–brain
barrier, neuroprotection
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Human immunodeficiency virus (HIV) is a neurotropic virus that enters the brain
shortly after infection. It has been reported that HIV enters the central nervous system
(CNS) via infected monocytes that traverse the blood–brain barrier (BBB) to replenish perivascular macrophages. Brain macrophages and microglial cells are reported to
be the key cells productively infected with HIV, and a few studies have also reported
HIV infection in astrocytes,1,2 which results in HIV-associated neurocognitive disorders
(HAND).3 Although very few reports suggest neurons being infected by HIV,4–6 but
postmortem studies of brains of patients with HAND show decreased synaptic plasticity/
function at various levels. Synaptic plasticity is defined as a change in efficacy/strength
of synapses (spine formation and maintenance of synaptic architecture) in response to
the external stimuli. Neuronal plasticity dysregulation can be seen at the cellular level
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by decreased spine density and synaptodendritic damage6 and
at the systemic levels with gray and white matter atrophy7,8
in both cortical and subcortical regions.9,10
Matrix metalloproteinases (MMPs) are a family of
endopeptidases that play a major role in the degradation of
most extracellular matrix proteins, wound healing, and tissue
morphogenesis.11–14 Tissue inhibitors of metalloproteinases
(TIMPs) are a family of proteinase inhibitors that control the
activity of MMPs in vivo by binding in 1:1 stoichiometry.15,16
Disruption of this balance is seen in various pathological
conditions such as neuroAIDS,17 Alzheimer’s disease,18 multiple sclerosis,19 brain tumors,20 epilepsy,21 and excitotoxic/
neuroinflammatory processes.22 In the case of HIV infection, once the HIV enters into the CNS, it leads to neuronal
damage, which in turn causes cognitive issues (eg, attention,
memory, language, problem solving, and decision-making),
and eventually leads to the HAND. Due to such diverse
roles in disease advancement, MMPs can serve as a promising therapeutic target, leading to the development of many
small-molecule or broad-spectrum MMP inhibitors. But
issues like off-target effects, ineffective therapeutic plasma
levels, and toxicity (eg, musculoskeletal toxicity) lead to the
failure of these compounds at early stages of the clinical trials
(eg, studies related to cancer and arthritis).23–26 Among all
inhibitors, TIMP1 has strong affinity for MMP-9 and holds
great therapeutic value in a wide variety of inflammatory and
vascular diseases and in cancer.27 In our previous studies,
we observed that TIMP1 is one of the highly downregulated
synaptic plasticity genes in HIV-infected neuronal cells.6
TIMP1 also acts as a neuroprotective agent in HIV infection
by protecting neurons from apoptosis and by preserving the
neuronal architecture.28 However, like most proteins, TIMP1
does not cross the BBB and the native form has a short halflife (,4 hours), rapid clearance, and low bioavailability,
thus limiting its application as a neuroprotecting agent for
CNS diseases.29
Nanotechnology is a platform to develop promising and
novel drug delivery systems in medicine, and significant
research exploring this novel technology has been focused on
the delivery of different drugs/proteins/therapeutic agents to
brain. Various kinds of drug delivery approaches to deliver
drugs across the BBB are being pursued including the use of
macrophage-mediated transport, receptor-mediated transport,
and use of lipid carrier and tagging drugs to ligands through
a carrier.30 Unfortunately, in vivo strategies like viral vector
upregulation, direct injection into the brain, transnasal, infusion pump-mediated, and transient disruption of BBB lack
practical relevance for patient treatment.31–33 In clinical trials,
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systemic side effects are the limiting factors observed while
delivering the optimum doses that have therapeutic effects
within the brain.34 It is necessary to develop innovative
technologies to deliver various neurotropic factors across
the BBB to reduce the neurotoxic effects observed in various
diseases. More recently, due to the intrinsic magnetic properties, magnetic nanoparticles (MNPs) have gained increasing
importance owing to the advantage of tracking them through
imaging methods. Along with our reports, several other
in vitro and in vivo studies have reported the use of magnetically guided drug delivery systems.35–40 Previously, our
group has shown the application of magnetic nanocarriers
for delivering anti-HIV drugs and neuroprotective agents
across the BBB using noninvasive external magnetic force
and demonstrated that this target-specific CNS strategy can
be used for the treatment of neuroAIDS.41,42 Recently, we also
developed a novel layer-by-layer magnetic nanoformulation
(NF) to deliver an anti-HIV drug and a latency reactivating
agent across the BBB in a sustained-release manner for
1 week for the treatment of neuroAIDS.43 The magnetic
platform will help for speedy navigation of the drug-loaded
nanocarrier to the target (brain), prevent reticuloendothelial
system uptake of the drug, and reduce off-target effects. In
the present study, we evaluated the role of TIMP1 protein in
neuroprotection by regulating the HIV infection, oxidative
stress, and spine density and its implication in prevention
of HAND using nanotechnology platform. We synthesized
MNP-loaded TIMP1 NF, tested its release kinetics and
transmigration across BBB using an in vitro model, and
observed the neuroprotective effect of TIMP1 in HIV-1infected neuronal cells.

Materials and methods
Synthesis of super paramagnetic iron
oxide nanoparticles
The iron oxide (Fe3O4) magnetic nanoparticles (MNPs)
were synthesized according to the coprecipitation method
as described previously.43,40

Characterization of MNPs
Synthesized MNPs were characterized for size and shape
using transmission electron microscopy (TEM; Phillips
CM-200, 200 kV operated at 80 kV) as described previously.43
The hydrodynamic radius, size distribution, and surface
charge measurement of TIMP1-loaded and -unloaded
MNPs were carried out at 25°C using Malvern Zetasizer
(dynamic laser scattering, Nano ZS; Malvern Instruments,
Inc., Westborough, MA, USA).
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Time kinetics, drug-binding isotherm, and
in vitro release studies of TIMP1
TIMP1 protein was purchased from the Life Technologies
(Catalog no 10934-H08H). To determine the time kinetics of
direct binding of TIMP1 protein on MNPs, different amounts
of MNPs (range: 5–20 µg) were added to 5 µg of TIMP1
and incubated in phosphate-buffered saline (PBS) (pH 7.4)
for 0, 10, 20, 30, and 60 minutes at room temperature (RT).
The amount of TIMP1 bound (% binding) to the MNPs was
determined by estimating the concentration of TIMP1 in
the unbound fraction (supernatant) of the mixture using a
UV nanospectrophotometer (Synergy™ HT Multi-Mode
Microplate Reader; BioTek Instrument, Inc., Winooski, VT,
USA) at 280 nm. TIMP1 + MNP NF (5 µg MNPs with 5 µg
TIMP1) release studies were performed in vitro in an Eppendorf tube containing 1,000 μL of PBS (pH 7.4) incubated at
37°C in an incubator; aliquots of release samples were collected at preset interval times (every 30 minutes) and aliquots
of the same volume were replaced with fresh PBS solution
to maintain sink condition. The cumulative TIMP1 release
percentage was obtained using the amount of TIMP1 released
from the total amount of TIMP1 loaded and was determined
spectrophotometrically at λmax of 280 nm.

Cell culture and reagents
SK-N-MC neuroblastoma cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA; catalog no HTB-10). HIV-1Ba-L (clade B, macrophage-tropic
[R5] virus) was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH) (Washington DC, USA;
AIDS Reagent Program, catalog no 510).

HIV-1 infection of human SK-N-MC cells
An established laboratory protocol was used for infecting
the SK-N-MC cells with HIV,6 with slight modifications.
Briefly, the SK-N-MC (1×105 cells) cells were grown
overnight in six-well plates in the Dulbecco’s Modified
Eagle’s Medium, and these cells were activated by treating
with polybrene (10 µg/mL) for 6–7 hours before the infection. The cells were infected with optimized concentration
(20 ng) of HIV-1 clade B virus overnight, were washed to
remove the unbound virus, and were incubated for a further
5 days. On the fifth day, TIMP1 solution or MNP NF containing TIMP1 was added to these cells and incubated for
48 hours. The culture supernatant collected after 7 days of
infection was used for the p24 antigen estimation using an
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enzyme-linked immunosorbent assay (ELISA) kit (catalog
no 0801200; ZeptoMetrix Corp., Buffalo, NY, USA). Control
cells (without HIV, TIMP1/MNP–TIMP1) were included in
the setup of all experiments.

In vitro BBB preparation, validation, and
transmigration assay
The BBB model was prepared as described by Persidsky
et al44 and modified by us.43 Briefly, in a bicompartmental
transwell culture plate (product no 3415; Corning Life
Sciences, Reynosa, Mexico), the in vitro BBB model was
prepared. An insert with 10 µm thick polycarbonate membrane possessing 3.0 µm pores separates the upper chamber
of this plate from the lower chamber. In a sterile 24-well
cell culture plate with the insert, human brain microvascular
endothelial cells in the upper chamber and human astrocytes
on the underside of lower chamber were grown to confluency. To assess the effect of MNP + TIMP1 NF on integrity of the in vitro BBB model, after transmigration assay,
paracellular transport of fluorescein isothiocyanate–dextran
(FITC–dextran) was measured.43 Briefly, 100 mg/mL FITC–
dextran (Sigma-Aldrich Co., St Louis, MO, USA) was added
to the upper chamber of the inserts and further incubated for
6 hours. Samples were collected from the bottom chamber
after 6 hours and relative ﬂuorescence was measured at an
excitation wavelength of 485 nm and an emission wavelength of 520 nm using Synergy HT Multi-Mode Microplate
Reader instrument (Biotek Instrument, Inc.). FITC–dextran
transport was expressed as percentage of FITC–dextran
transported across the BBB into the lower compartment
compared to negative control. Intactness of in vitro BBB
was determined by measuring the transendothelial electrical resistance (TEER) using Millicell ERS microelectrodes
(EMD Millipore, Billerica, MA, USA). On the fifth day of
BBB preparation, when the ideal integrity of the BBB was
achieved (by measuring TEER values), transmigration assay
of MNP-bound TIMP1 was performed. MNP + TIMP1 NF
was added to the upper chamber of the BBB preparation and
incubated at 37°C with/without magnetic force of (0.08 T)
placed externally below the transwell basolateral chamber.
MNP + TIMP1 NF was collected from the lower chamber at
different time points (ie, 1, 2, 3, and 6 hours) and % transmigration was analyzed for all the different time points using
ammonium thiocyanate-based photometric assay.43

Intracellular uptake analysis
Human neuroblastoma SK-N-MC cells were seeded in sixwell plates at a concentration of 1×106 cells. After 24 hours,
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cells were treated with equal quantity of FITC-tagged
MNP + TIMP1 NF for 3–24 hours. Cells were rinsed with
PBS, and to quantify the cellular uptake of TIMP1-loaded
nanoparticle levels, the flow cytometer was used.45 These
cells were harvested at different time points (3–24 hours)
after treatment, and 1 million cells were aliquoted in
12×75 mm polystyrene falcon tubes (BD Biosciences, San
Jose, CA, USA; catalog no 352058) and fixed with Cytofix
solution (BD Biosciences). Cells for uptake were analyzed
in a flow cytometer (BD Accuri Cytometers Inc., Ann Arbor,
MI, USA), and a total of 10,000 events were collected for
each sample. The results were analyzed using the FlowJo
software (Tree Star Inc., Ashland, OR, USA). Cells were
gated based on cells with and without NF controls. Cells
positive for NF are shown as colored histograms and compared with controls.

Cytotoxicity assay
Cytotoxicity of MNPs alone and TIMP1-loaded MNP
NF was assessed by MTT cell viability assay using the
established protocol.46 SK-N-MC cells were seeded in sixwell tissue plates at a density of 1×105 cells per well and
infected with HIV as explained in the “HIV-1 infection of
human SK-N-MC cells” section. After 5 days of infection,
100 µL fresh media containing different amounts of Fe3O4
(5–20 µg), TIMP1 (50 ng–1 µg), and MNPs-bound TIMP1
was added (5–20 µg of MNPs loaded with 5 µg of TIMP1).
After 48 hours of incubation, 6-well plates were given a
media change with 1 mL medium and approximately 100 μL
of MTT solution (100 mg MTT/20 mL of PBS) was added
into each well and incubated at 37°C for 3 hours. Finally,
1 mL of stop solution (20% sodium dodecyl sulfate in 50%
dimethylformamide) was added into each well and the mixture was kept on a rocker for ~2 hours; the absorbance was
then read at 550 nm using a microplate reader (Synergy HT
Multi-Mode Microplate Reader; BioTek Instrument, Inc.).

Effect of TIMP1 on neuronal cell
protection from oxidative stress induced
by HIV-1 infection
Production of reactive oxygen species (ROS) in HIV-1 infection and/or after adding free TIMP1 or MNP-bound TIMP1
to SK-N-MC cells was detected by the dichlorofluorescein
diacetate assay (DCFDA) using the established protocol47
with few modifications. SK-N-MC cells were cultured in
six-well plates (1×105 cells) overnight to allow them to
adhere on the bottom surface of the plate. The next day,
after activation with polybrene, cells were infected with
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optimized concentration of HIV-1 for 5 days. On the fifth day,
TIMP1 or MNP + TIMP1 NF was added to these cells and
incubated for 48 hours. After 7 days of infection/treatment,
cells (100,000 cells per well) were transferred to 96-well
plates along with its media and incubated overnight. The
next day, negative control group wells were treated with
catalase (0.001 mg) for 2 hours. Further, cells were treated
with 100 mM DCFDA for 1 hour at 37°C, and finally, the
optical density was read in a microplate reader with excitation
wavelength of 485 nm and emission wavelength of 528 nm
(BioTek Instrument, Inc.). Cells treated with H2O2 for 2 hours
were considered as positive control. Untreated and uninfected
cells were considered as control cells. Test group results were
compared with the control group values.

Spine density measurement
Coverslips were sterilized using absolute alcohol and placed in
six-well culture plates and incubated for 2 hours at 37°C. After
incubation, SK-N-MC cells were cultured on the coverslips
and incubated overnight at 37°C. SK-N-MC cells were treated
with the polybrene for 6 hours and infected with the HIV (as
explained in the “HIV-1 infection of human SK-N-MC cells”
section) for 5 days. On the fifth day of infection, free TIMP1/
MNP-bound TIMP1 was added into the respective wells and
incubated for 48 hours. Seven days postinfection, SK-N-MC
cells were stained with the Dil (1,1′-dioctadecyl-3,3,3′,3′tetramethylindocarbocyanine perchlorate) stain.

Dil stain
SK-N-MC cells were washed with PBS once and fixed
with 4% formaldehyde for 30 minutes at RT. Then, cells
were stained with Dil stain (the fluorescent membrane
tracer) (10 μg/mL in PBS concentration) and incubated for
90 minutes at RT. To allow the transport of the dye, the
stained coverslips in six-well plates were incubated overnight in PBS. In the morning, these stained coverslips were
mounted on the glass slides with ProLong® Gold Antifade
Reagent (Thermo Fisher Scientific, Waltham, MA, USA)
and confocal microscopy was performed.

Confocal microscopy
The stained neuronal cells were observed for dendrites using
the TCS SP2 Leica Confocal Laser Scanning Microscope
using the 60× oil immersion objectives, an 88 nm argonion laser illumination, and a 2.5× confocal electronic zoom
setting. A series of optical serial sections of the cells were
used to obtain the best “two-dimensional” images of individual cells.
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All the experiments were performed in duplicate and repeated
three times. The obtained values were averaged and data
represented as mean ± standard error (SE). GraphPad Prism
software was used to analyze the data. One-way analysis of
variance was used to compare the data obtained between
the groups, and the results were considered significant at
P#0.05. The confocal images were analyzed for the spine
density using the ImageJ software.

Results
Formulation characterization and drug
release kinetics
MNPs were prepared per laboratory standardized protocol43
and characterized for size, shape, polydispersity index,
and TIMP1 loading. TEM studies show that nanoparticles
were in the range of 10±3 nm (TIMP1 loaded), as shown in
Figure 1A, and had excellent dispersion property (polydispersity index .0.178) in aqueous medium.
The synthesized MNPs were also analyzed for superparamagnetic property (magnetic hysteresis loops, range: +1,200
to −1,200 Oersted) and crystal structure (X-ray diffraction

spectroscopy); the results showed strong magnetic behavior
(revealed through no coercivity and remanence) and magnetitespecific peaks (data not shown). Also, the time kinetics of
TIMP1 (5 µg) loading with respect to MNP concentration
was evaluated – maximum binding of TIMP1 (4±0.51 µg,
corresponds to 80% loading) occurred as early as 10 minutes
when lowest amount of MNPs (5 μg) was used as shown in
Figure 1B (a and b), compared to higher time of incubation
or larger amount of MNPs. Zeta (ζ) potential showed overall
negative charge on MNPs (−30±4 mV) in deionized water,
which changed to +10±2 mV on TIMP1 loading, thus confirming the TIMP1 deposition on MNPs due to electrostatic bonding.
Furthermore, in vitro pharmacokinetic release studies showed
that 100% TIMP1 release from MNPs takes place in ~6 hours
in PBS (pH 7.4) at 37°C (Figure 1C).

In vitro BBB development and
MNP + TIMP1 NF transmigration
efficiency studies

The BBB transmigrability of the plain MNPs and MNPs +
TIMP1 NF was evaluated using an in vitro human BBB
model. The tightness of the developed in vitro BBB was
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Figure 1 Characterizations of MNP nanoformulation.
Notes: (A) Transmission electron microscopy of TIMP1-loaded MNPs; (B) binding kinetics of TIMP1 (5 µg) to MNPs: (a) effect of MNPs amount with respect to percentage
TIMP1 binding and (b) effect of time with respect to percentage TIMP1 binding; (C) in vitro release data: cumulative percentage release profile of TIMP1 from MNP
nanoformulation (5 µg of TIMP1 loaded onto 5 µg MNPs) was studied in PBS (pH 7.4) with 0.1% sodium azide at 37°C using 100 kD Micro Float-A-Lyzer (Spectrum Labs,
Cincinnati, OH, USA) dialysis membrane. Standard errors are shown for the mean of triplicate samples.
Abbreviations: TIMP1, tissue inhibitor of metalloproteinase-1; MNPs, magnetic nanoparticles; PBS, phosphate-buffered saline.
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Table 1 In vitro BBB model TEER values
Magnetic force

Untreated
well (control)

Plain
MNPs

TIMP1 + MNPs

No force
Magnetic force

362.5±9.7
362.6±6.5

371.8±5.6
368.4±10.5

360.6±9.5
360.2±2.6

Note: Data presented as mean ± standard deviation. n=5.
Abbreviations: BBB, blood–brain barrier; MNPs, magnetic nanoparticles; TEER,
transendothelial electrical resistance; TIMP1, tissue inhibitor of metalloproteinase-1.

determined by TEER values estimation after 5–6 days as per
our previously standardized protocol.43 Following the TEER
determination, 100 µL of cell culture medium containing
MNPs (5 µg) ± TIMP1 (4±0.51 µg) NF was added in the upper
chamber into the respective wells (24-well plate) and incubated in the presence or absence of external magnetic force
(0.8 T). As shown in Table 1, before applying the magnetic
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force, TEER values of all treatment groups were comparable
to the standard (untreated well) of 360±10 Ω/cm2. As per
our expectation, even after applying the magnetic force, we
did not observe any significant change in TEER value with
MNPs + TIMP1 NF treatment (as shown in Table 1) when
compared with untreated and plain MNP samples.
MNPs + TIMP1 NF ability with respect to BBB transmigration was verified by measuring the iron concentration
in the lower chamber after application of external magnetic
field for different time points. We observed that 40%±2.5%
of plain MNPs and 37.5%±1.5% of MNPs + TIMP1 NF
transmigrated across the in vitro BBB on magnetic treatment
(0.8 T, 2 hours) compared to no magnetic treatment for both
MNPs and MNPs + TIMP1 NF (shown in Figure 2A). Also,
no significant increase in nanoformulation transmigration
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Figure 2 MNPs + TIMP1 nanoformulation (NF) transmigration study using in vitro BBB model.
Notes: (A) Transmigration efficiency evaluation: MNPs, free TIMP1, and MNPs + TIMP1 NF were added in the upper chamber of the transwells, and samples were tested
for transmigration ability in the presence or absence of static magnet (0.8 T) placed underneath the cell culture plate for the 2 hours treatment; transmigrated samples were
collected from the bottom chamber, centrifuged, and estimated for iron content using iron assay; (B) effect of magnetic treatment time with respect to NF transmigration
efficiency: samples from the lower chamber at different time points, ie, 2, 4, and 6 hours, were collected, and transmigrated MNPs + TIMP1 NF was collected from the bottom
chamber, centrifuged, and calculated for iron content using iron assay. (C) BBB integrity analysis using the FITC–dextran transport assay: FITC–dextran transport was measured
for MNPs/MNPs + TIMP1 NF after 2 hours’ magnetic treatment, and FITC–dextran (molecular weight 40,000 Da) was added to the upper chamber of the insert. After
30 minutes’ incubation, relative ﬂuorescence unit from the lower chamber of the transwell was measured. Results were expressed as % FITC–dextran transport with respect
to the untreated control cultures (−ve control = no cell and +ve control = with all BBB cells) and represented as mean ± SE of independent experiments. ***P#0.001.
Abbreviations: BBB, blood–brain barrier; SE, standard error; FITC, fluorescein isothiocyanate; TIMP1, tissue inhibitor of metalloproteinase-1; NF, nanoformulation; MNPs,
magnetic nanoparticles; NS, not significant; ctrl, control; M, Magnet.
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was observed on applying longer period of magnetic field
as shown in Figure 2B.
Further, the integrity/intactness of BBB was evaluated
using paracellular transport of FITC–dextran as described
earlier in the methodology, with FITC molecule used as the
detection moiety to confirm the membrane intactness. As can
be seen from Figure 2C, only 7.25%±3% FITC is transported
(upper to lower chamber) for both MNPs and MNPs + TIMP1
NF in comparison to ~100% transport for negative control
(transwell without any BBB cells), thus proving that MNPs +
TIMP1 NF transmigration under external magnetic field does
not affect the BBB integrity and that the nanoformulation is
safe to be used for clinical application.

In vitro cytotoxicity and cell uptake studies
To explore the effect of different amounts of free TIMP1,
MNPs, and MNP-tagged TIMP1 on SK-N-MC cells infected
with HIV, the MTT assay was used. We did not observe
any significant cytotoxicity in HIV-infected SK-N-MC cells
exposed to free TIMP1 (up to 1 µg), MNPs (up to 20 µg), and
MNP-tagged TIMP1 (5 µg MNPs + 5 µg TIMP1) combination when compared to the control uninfected and untreated
SK-N-MC cells (Figure 3), thus suggesting NF is nontoxic
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Figure 3 Cytotoxicity studies in SK-N-MC cells for free and TIMP1 + MNPs
nanoformulation components.
Notes: Figure shows the percentage of cells viable after treatment with different
amounts of MNPs (5–20 µg/mL) or free TIMP1 (50 ng–1 µg) or MNPs + TIMP1
nanoformulation. SK-N-MC cells (1×105 cells) were grown in the six-well culture
plates, and cells were infected with 20 ng of HIV-1 clade B overnight. Unbound virus
was washed, and cells were infected for 7 days. On fifth day of infection, TIMP1/
MNPs/MNPs + TIMP1 was added at different amounts into the respective wells and
incubated for 48 hours. Seven days postinfection, cell viability was measured using
the MTT assay. *P#0.05.
Abbreviations: HIV, human immunodeficiency virus; TIMP1, tissue inhibitor of
metalloproteinase-1; NF, nanoformulation; MNPs, magnetic nanoparticles; NS, not
significant.
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in nature and should not have any safety concerns for any
preclinical use.
Also, the quantitative analysis of MNPs + TIMP1 NF
for cell uptake was performed by using the flow-cytometry.
Our results showed that maximum cell uptake took place as
early as 3 hours (~50%) and that there was no significant
difference in cell uptake (percentage of cells positive for
FITC-tagged NF) with longer incubation time, ie, up to
24 hours (as shown in Figure 4).

Decreased HIV-1 infection in SK-N-MC
neuronal cells exposed to MNP-bound
TIMP1
SK-N-MC cells were infected with HIV for 5 days, and
free TIMP1 alone or MNP-tagged TIMP1 was added to the
infected cells and incubated further for 48 hours. After a total
of 7 days of infection, supernatant was collected and HIV
infectivity in these cells was measured using the p24 ELISA.
Although we did not expect any difference in HIV infection
with TIMP1 treatment, surprisingly, we observed significant
reduction of HIV infection in TIMP1-treated (starting from
250 ng of TIMP1) and MNPs + TIMP1 NF-treated SK-N-MC
cells (Figure 5).

Reduced oxidative stress in HIV-infected
SK-N-MC neuronal cells exposed to free
TIMP1 or MNP-bound TIMP1
HIV infection is known to induce oxidative stress by production of ROS in different types of cells. To see the effect
of HIV infection on ROS production in SK-N-MC cells
and to investigate the neuroprotective role of TIMP1, we
analyzed the ROS production in HIV-infected cells exposed
to the solution-phase free TIMP1 and MNPs + TIMP1 NF.
We observed significant reduction of ROS production in
HIV-infected SK-N-MC cells exposed to solution-phase
free TIMP1 when compared to the cells infected with HIV
alone. In case of MNPs + TIMP1 NF exposed HIV-infected
SK-N-MC cells, we observed significantly reduced ROS
production when compared to the cells infected with HIV
alone. We did not find significant difference in ROS production between HIV-infected cells exposed to free TIMP1 and
MNPs + TIMP1 NF (Figure 6).

TIMP1 recovers spine density in
HIV-infected neurons
In the HIV-infected SK-N-MC cells, we observed significantly
reduced spine density when compared to the uninfected control cells. When these cells were exposed to free TIMP1 alone
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Figure 4 Quantitative analysis of uptake of FITC-tagged MNPs + TIMP1 NF in SK-N-MC cells using the flow cytometry.
Notes: SK-N-MC cells were exposed to 5 µg of FITC-labeled MNPs + TIMP1 NF for 3, 6, 12, and 24 hours. Uptake of the NF was measured by the fluorescence in the
SK-N-MC cells using the flow cytometry. For each sample, 10,000 events were collected, and cells were gated based on the cells without NF (pink-line histogram) or control
(A). Colored histograms show cells positive for NF with shifted mean fluorescence intensity compared to controls. The representative figures for uptake at 3 hours (B) and
24 hours (C) are presented. Histograms represent cells treated with 5 µg of FITC-tagged NF for 3 hours (blue) and 24 hours (orange) (D), which show 49.85% and 50% cells
are positive for MNPs + TIMP1 NF, respectively, when compared with the untreated cells. Histograms show an overlay for time points (3 and 24 hours) (D).
Abbreviations: FITC, fluorescein isothiocyanate; TIMP1, tissue inhibitor of metalloproteinase-1; NF, nanoformulation; MNPs, magnetic nanoparticles.

or MNP-bound TIMP1, we observed significant recovery of
spine density when compared to the HIV-infected cells. We
did not find significant difference in the recovery of the spine
density between free TIMP1-treated cells and MNP-bound
TIMP1-treated cells (Figure 7).

Discussion
Neuronal cell death or apoptosis by means of oxidative stress
in HIV-infected patients is one of the key mechanisms responsible for the cognitive and motor dysfunctions.48,49 In our
previous studies, we have observed dysregulation of synaptic
plasticity genes and decreased spine density in HIV-infected
neuronal cells.6 Therefore, there is a need to investigate the
therapeutic molecules that can induce neuroprotection in
HIV-infected patients. In vitro and in vivo models of brain
trauma and stroke suggest that TIMP1 is neuroprotective
4294
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and that overexpression of TIMP1 prevents the BBB leakage
and reduces neuronal cell death.50 Downregulation of TIMP1
was observed in HIV-infected macrophages and vascular
endothelial cells.51 In our previous studies, among different
dysregulated genes, TIMP1 was one of the highly downregulated synaptic plasticity genes in HIV-infected neuronal cells.6
In addition to our in vitro reports, in chronically HIV-infected
patients, decreased TIMP1 protein expression was observed
in brain tissue and cerebrospinal fluid.52 TIMP1 is not only
the inhibitor of MMPs-1–3, -7–13, and -16 but also acts as
a candidate synaptic plasticity gene (induces expression of
immediate early response genes) leading to the development
of long-term potentiation, which plays a major role in forming
learning and memory.53–55 TIMP1 has been reported to have
neuroprotective effects equivalent to that of brain-derived
neurotropic factor.50 Therefore, supplementing TIMP1 may
International Journal of Nanomedicine 2016:11
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Figure 5 Decreased HIV infection levels in SK-N-MC cells treated with free TIMP1
or MNPs + TIMP1 NF.
Notes: SK-N-MC (1×105 cells) were grown in the six-well culture plates, and cells
were infected with 20 ng of HIV-1 clade B overnight. Unbound virus was washed
with PBS, and cells were infected for 7 days. On fifth day of infection, free TIMP1/
MNPs + TIMP1 NF was added into the respective wells and incubated for 48 hours.
Seven days postinfection, HIV infection levels were measured using the p24 ELISA.
*P#0.05, **P#0.01.
Abbreviations: TIMP1, tissue inhibitor of metalloproteinase-1; NF, nanoformulation;
MNPs, magnetic nanoparticles; HIV, human immunodeficiency virus; PBS, phosphatebuffered saline; ELISA, enzyme-linked immunosorbent assay; NS, not significant.
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Figure 6 Decreased ROS production in HIV-infected SK-N-MC cells treated with
free TIMP1 or MNPs + TIMP1 NF.
Notes: SK-N-MC (1×105 cells) were grown in the six-well culture plates, and cells
were infected with 20 ng of HIV-1 clade B overnight. Unbound virus was washed
with phosphate-buffered saline, and cells were infected for 7 days. On fifth day of
infection, TIMP1/MNPs/MNPs + TIMP1 NF was added into the respective wells and
incubated for 48 hours. Seven days postinfection, ROS production was measured
using the ROS assay. *P#0.05, **P#0.01, ***P#0.001.
Abbreviations: ROS, reactive oxygen species; RFU, relative ﬂuorescence unit;
TIMP1, tissue inhibitor of metalloproteinase-1; NF, nanoformulation; MNPs,
magnetic nanoparticles; HIV, human immunodeficiency virus; NS, not significant.

International Journal of Nanomedicine 2016:11

be helpful in reducing the neuronal damage induced by the
HIV infection. Due to the selectively permeable nature of
the BBB, novel and effective delivery methods are needed
for the successful delivery of therapeutic molecules across the
BBB. In this study, we used MNPs for the delivery of TIMP1
protein across the BBB for neutralizing the neuropathogenesis
induced in HIV infection. We observed successful delivery of
TIMP1 nanoformulation (~40%) across in vitro BBB model
on application of external magnetic field. Also, results showed
no damage to BBB integrity after transmigration of NF as
shown in Figure 2. The percentage of transmigration of free
MNPs or MNP-bound TIMP1 NF transmigration across the
BBB is in the range of our previous studies.43,56
We also did not observe neuronal cytotoxicity of the free
TIMP1 (up to 1 µg), free MNPs (up to 20 µg), and MNPbound TIPM1 NF. In this study, surprisingly, we observed
significantly reduced HIV infection in SK-N-MC cells in
the presence of free TIMP1 and MNP-bound TIMP1 NF
when compared with HIV controls. But we did not see any
significant difference in the HIV infection between the group
of SK-N-MC cells grown in the presence of free TIMP1 and
MNP-bound TIMP1 protein. Although TIMP1 controls the
activity of MMP-1–3, -7–13, and -16, it has the strongest
affinity for the MMP-2 and -9. In HIV-infected patients,
increased secretion of MMP-2 and MMP-9 induces extracellular matrix degradation, which leads to the disruption
of endothelial barriers, thus facilitating the spread of HIV
infection in tissues.57 Reduced TIMP1 expression over time
has been reported to potentially contribute to an increased
propensity of HIV infection within the brain parenchyma.58
Based on our results and previous reports, it is indicative that
supplementation of soluble-phase TIMP1 or MNP-bound
TIMP1 results in the reduced infectivity levels in the neuronal
cells and that this may be due to the inhibition of MMP-2
and MMP-9 activity. In a similar fashion, in glial cells and
peripheral blood mononuclear cells, antiretroviral therapy
was reported to inhibit the expression of MMP, indicating that
the beneficial effects of antiretroviral therapy in HIV-infected
patients may also be due to the reduction of MMP levels.57,59
Therefore, mechanisms for reducing HIV infectivity in the
presence of TIMP1 need to be further investigated in various
types of peripheral and CNS cells.
There are many strong evidences that support the fact
that various materials at the nanometer range have the ability to induce the production of ROS.60 Hence, we wanted to
determine whether our NFs had any effects on the production
of ROS as it involved iron oxide nanoparticle as a carrier.
We did not observe any cytotoxicity/oxidative stress with
the amount of MNPs that we used in our studies. This is in
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Figure 7 TIMP1 recovers spine density in human immunodeficiency virus (HIV)-infected neuronal cells.
Notes: SK-N-MC cells were infected with HIV for 7 days. On the fifth day of HIV infection, free TIMP1 or MNPs + TIMP1 nanoformulation was added to the culture.
(A) Control cells: long spines in high number can be observed on a dendritic length, (B) HIV-infected cells: loss of number of spines can be observed on a dendritic length
when compared to the control. (C) HIV-infected cells in the presence of free TIMP1: recovery of spines on the dendrite length when compared to the HIV-infected cells. (D)
HIV-infected cells in the presence of MNPs + TIMP1 NF: recovery of spines on the dendrite length when compared to the HIV-infected cells.
Abbreviations: TIMP1, tissue inhibitor of metalloproteinase-1; MNPs, magnetic nanoparticles; HIV, human immunodeficiency virus; NF, nanoformulation.

agreement with the previous reports that cytotoxicity and
oxidative stress induction by MNPs in the cells are dose
dependent.61 Furthermore, in the presence of both solutionphase and MNP-bound TIMP1, we observed significantly
reduced oxidative stress induced by HIV infection. Several
reports indicate that oxidative stress plays a major role in
neuronal damage and cognitive disorders in HIV-infected
patients.62,63 In this study, we observed that reduced oxidative
stress could be due to the decreased HIV infection because
of release of TIMP1 from the MNP NF. We also observed
the effect of free TIMP1 and MNP-bound TIMP1 exposure
on the recovery of spine density in HIV-infected neuronal
cells. In both the test groups, we observed recovery of spine
density compared to the HIV-infected cells. The recovery of
spine density may also be due to the decreased HIV infection, reduced oxidative stress, and induced synaptic plasticity
genes expression. Also, the recovery of spine density plays
a major role in the generation of long-term potentiation and
formation of long-term memory. Therefore, recovery of
spine density may help in the recovery of synaptic plasticity
and reduce the neurocognitive impairments observed in the
HIV-infected patients. Therefore, based on these exciting and
novel findings, in future, we would like to test the efficacy
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of the developed NF in vivo to take it to the clinical level for
neuroprotection in HIV-infected patients.

Conclusion
Our results indicate that MNP-bound TIMP1 NF may act as a
neuroprotective agent by decreasing the HIV infection levels
and oxidative stress, thus enabling the recovery of neuronal
spine density. Due to the impermeability of the BBB, the
use of MNP-bound TIMP1 helps in successful delivery of
the TIMP1 protein across the BBB into the neuronal cells. In
conclusion, these results highlight a novel function, mechanism, and direct role of TIMP1 as a neuroprotective agent in
HIV-induced neurotoxicity, signifying MNPs + TIMP1 NF
delivery as a therapy for neurodegenerative diseases.
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